Related papers: Toward a closed-loop subcutaneous delivery of L-DO…
Parkinson's disease (PD) is caused by the progressive loss of dopaminergic cells in substantia nigra pars compacta (SNc). The root cause of this cell loss in PD is still not decisively elucidated. A recent line of thinking traces the cause…
Density functional theory and ab initio methods have been employed to address the impacts of hydroxyl (OH) group substitutions on the physico-chemical properties of levodopa (or L-dopa) against the natural amino acids, phenylalanine and…
Parkinson's Disease (PD) medication management presents unique challenges due to heterogeneous disease progression and treatment response. Neurologists must balance symptom control with optimal dopaminergic dosing based on functional…
Parkinson's disease (PD) is a progressive neurodegenerative disease, and it is caused by the loss of dopaminergic neurons in the basal ganglia (BG). Currently, there is no definite cure for PD, and available treatments mainly aim to…
Parkinson's Disease afflicts millions of individuals globally. Emerging as a promising brain rehabilitation therapy for Parkinson's Disease, Closed-loop Deep Brain Stimulation (CL-DBS) aims to alleviate motor symptoms. The CL-DBS system…
Deep brain stimulation (DBS) is an advanced surgical treatment for the symptoms of Parkinson's disease (PD), involving electrical stimulation of neurons within the basal ganglia region of the brain. DBS is traditionally delivered in an…
The current body of research on Parkinson's disease (PD) screening, monitoring, and management has evolved along two largely independent trajectories. The first research community focuses on multimodal sensing of PD-related biomarkers using…
Parkinson's disease is a progressive and slowly developing neurodegenerative disease, characterized by dopaminergic neuron loss in the substantia nigra region of the brain. Despite extensive research by scientists, there is not yet a cure…
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, yet there is no disease-modifying therapy up to this date. The biological complexity underlying PD hampers the investigation of the principal…
Parkinson's Disease (PD) is a progressive nervous system disorder that has affected more than 5.8 million people, especially the elderly. Due to the complexity of its symptoms and its similarity to other neurological disorders, early…
Introduction: The blood-brain barrier (BBB) protects the central nervous system but prevents most neurotherapeutics from reaching effective concentrations in the brain. BBB-penetrating peptides (BBBPs) offer a promising strategy for brain…
Programmable lipid nanoparticles, or LNPs, represent a breakthrough in the realm of targeted drug delivery, offering precise spatiotemporal control essential for the treatment of complex diseases such as cancer and genetic disorders. In…
The basal ganglia (BG) show a variety of functions for motor and cognition. There are two competitive pathways in the BG; direct pathway (DP) which facilitates movement and indirect pathway (IP) which suppresses movement. It is well known…
Parkinsons disease (PD) diagnosis is challenging due to subtle early clinical signs. F-DOPA PET is commonly used for early PD diagnosis. We explore the potential of machine-learning (ML) based EEG features extracted from single-channel EEG…
Parkinson's Disease (PD) is the second most common neurodegenerative disease in humans. PD is characterized by the gradual loss of dopaminergic neurons in the Substantia Nigra (SN). Counting the number of dopaminergic neurons in the SN is…
Peptide nucleic acids (PNAs) are artificial nucleic acids with a peptide backbone instead of sugar phosphate backbone of DNA or RNA. Their resistance to degradation, selectivity and greater binding affinity in comparison to usual nucleic…
The study involved 56 patients with advanced and late stages of Parkinsons disease, which could be considered as potentially requiring neurosurgical treatment-electrical stimulation of deep brain structures. An algorithm has been developed…
Parkinson's disease is a neurological condition that occurs in nearly 1% of the world's population. The disease is manifested by a drop in dopamine production, symptoms are cognitive and behavioural and include a wide range of personality…
Parkinson's disease (PD) is a slowly progressive, debilitating neurodegenerative disease which causes motor symptoms including gait dysfunction. Motor fluctuations are alterations between periods with a positive response to levodopa therapy…
This paper presents a delay-dependent parameter-varying control design approach to address the automated blood pressure regulation problem in the critical patient resuscitation using closed-loop administration of vasopressors. The mean…